Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition where excessive fat accumulates in liver cells.
It has been observed that approximately 30% of MASLD patients develop metabolic dysfunction-associated steatohepatitis (MASH). The development of the disease may lead to liver cirrhosis and possible development of hepatocellular carcinoma. This highlights MASLD as the leading cause of liver disease worldwide and its prevalence is predicted to increase by 2030 if current trends remain as today.
Recent progress in liver disease research has brought about significant progress in understanding and addressing metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD). Collaborative efforts among leading liver disease societies have resulted in updated nomenclature and diagnostic criteria for MASLD, aiming to provide clarity and improve patient identification without stigmatization.
MASLD affects over a quarter of the global population and presents various risk factors, including obesity, impaired glucose metabolism, and high blood pressure. Understanding these factors is crucial for preventing disease progression to metabolic dysfunction-associated steatohepatitis (MASH) and associated complications like liver cirrhosis and hepatocellular carcinoma.
Despite challenges in diagnosing and monitoring MASLD and MASH due to the lack of approved biomarkers, ongoing research efforts offer hope for improved diagnostics and personalized treatment approaches. Promising biomarker candidates include hemoglobin levels, fibroblast growth factor 21 (FGF21), and cytokeratin-18 (CK18), among others, providing valuable insights into disease progression.
At Mercodia, we are dedicated to supporting liver disease research with our range of ELISAs for studying MASLD and MASH biomarkers. Our assays offer high accuracy and consistency, providing researchers with valuable tools for advancing our understanding of liver disease.
| Oxidized LDL |
| Oxidized LDL ELISA 10-1143-01 |
As the prevalence of MASLD continues to rise globally, staying informed about the latest research and breakthroughs is essential. Download our comprehensive white paper about MASLD and MASH and discover how advancements in biomarker research are shaping the future of liver disease management.
Advances in MASLD and MASH: nomenclature, characteristics, and biomarkers
We gladly support you by keeping you updated on our latest products and the developments around our services.
Direct contact technical support
Find products for your research
